Statement on Chloroquine and Hydroxychloroquine

TMA COVID-19 Task Force

JUNE 19, 2020

Per the National Institutes of Health (NIH) COVID-19 Treatment Guidelines:

**At present, there are no Food and Drug Administration (FDA)-approved drugs for the treatment of COVID-19.**

- The COVID-19 Treatment Guidelines Panel **recommends against** the use of **chloroquine** or **hydroxychloroquine** for the treatment of COVID-19, except in a clinical trial.

- The COVID-19 Treatment Guidelines Panel **recommends against** using **high-dose chloroquine** (600 mg twice daily for 10 days) for the treatment of COVID-19.

- The COVID-19 Treatment Guidelines Panel **recommends against** the use of **hydroxychloroquine plus azithromycin** for the treatment of COVID-19, except in the context of a clinical trial.

- **Given the risk of dysrhythmias, the FDA cautions against the use of chloroquine or hydroxychloroquine for the treatment of COVID-19** outside of a hospital or clinical trial. When chloroquine or hydroxychloroquine is used, clinicians should monitor the patient for adverse effects, especially prolonged QTc interval.

- On June 15, the FDA revoked the emergency use authorization (EUA) that permitted the use of chloroquine and hydroxychloroquine donated to the Strategic National Stockpile to treat certain patients with COVID-19.

**Prophylaxis**

The COVID-19 Treatment Guidelines Panel **does not recommend** the use of any agents for SARS-CoV-2 pre-exposure prophylaxis (PrEP) OR post-exposure prophylaxis (PEP) outside the setting of a clinical trial.

**At present, no agent given before an exposure (i.e., as PrEP) is known to be effective in preventing SARS-CoV-2 infection, and no agent is known to be effective for preventing SARS-CoV-2 infection after an exposure (i.e., as PEP).**

Clinical trials using hydroxychloroquine, chloroquine, or HIV protease inhibitors as PrEP or PEP are in development or underway.

Further, the Texas Medical Association supports the guidance by the Texas State Board of Pharmacy which places medical limitations on the prescribing of hydroxychloroquine as a means to conserve this drug for patients for whom it is medically necessary.
NOTICE: The information and opinions presented as part of this publication should not be used or referred to as primary legal sources, nor construed as establishing medical standards of care for the purposes of litigation, including expert testimony. The standard of care is dependent upon the particular facts and circumstances of each individual case and no generalization can be made that would apply to all cases. This information should NOT be considered legal advice and receipt of it does not create an attorney-client relationship. **This is not a substitute for the advice of an attorney.** The Texas Medical Association (TMA) provides this information with the express understanding that 1) no attorney-client relationship exists, 2) neither TMA nor its attorneys are engaged in providing legal advice and 3) the information is of a general character. Although TMA has attempted to present materials that are accurate and useful, some material may be outdated and TMA shall not be liable to anyone for any inaccuracy, error or omission, regardless of cause, or for any damages resulting therefrom.

Certain links provided with this information connect to websites maintained by third parties. TMA has no control over these websites or the information, goods or services provided by third parties. TMA shall have no liability for any use or reliance by a user on these third-party websites or information provided by third parties.